

Corporate Action Notice

October 5, 2015

Cash Distribution Resulting from the Sale of Rights

Rhoen-Klinikum AG

CUSIP: 76240P104

DR Ticker Symbol: RKAGY

Ratio: (DR: Underlying Share): 2:1

**BNY MELLON HAS ESTABLISHED
THE FOLLOWING DATES FOR THIS
CORPORATE ACTION:**

DR Record Date:	Oct 07, 2015
DR Payment Date:	Oct 16, 2015
Gross Rate per DS:	\$0.044272
Depository Fee per DS:	\$0.000000
Net Rate per DS:	\$0.044272

Rhoen-Klinikum AG announced a distribution of Rights to its Ordinary shareholders. The Rights were allocated as follows: 1 Right(s) were issued for every 1 Ordinary share(s) held as of the local record date of Sep 10, 2015.

The Rhoen-Klinikum AG Rights were not registered under the United States Securities Act of 1933, therefore we were not permitted to pass the Rights on to the holders of Depositary Receipts ("DRs"). As a result, BNY Mellon has sold the Rights in the local market and the proceeds received from the sale will be distributed to the DR holders of Rhoen-Klinikum AG.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis
Richard J Maehr
+ 1 212 815 2267
addrdesk@bnymellon.com

LONDON

Damon Rowan
Vice President
+ 44 207 163 7511
damon.rowan@bnymellon.com

HONG KONG

Herston Powers
Vice President
+ 852 2 840 9868
herston.powers@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon as depository may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. The conversion rate reflects a foreign currency ("FX") transaction ("FX Trade") executed by BNY Mellon as principal counterparty and not as agent, fiduciary or broker. BNY Mellon has no obligation to obtain the "best price" for any FX Trade. BNY Mellon earns revenue on the FX Trade based on, among other things, the difference between the rate it assigns to the FX Trade and the rate that it pays and receives for purchases and sales of currencies when engaging in any offsetting trades for its own account. The decisions BNY Mellon makes on when and how to enter into any offsetting trades, as well as other factors (including but not limited to liquidity and market volatility), affect the revenue BNY Mellon earns on FX Trades.



BNY MELLON